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A murine model of osteosarcoma was developed to investigate the association between the expression of VEGF and the progres-
sion of osteosarcoma. Two human osteosarcoma cell lines with distinct VEGF expressions were introduced into proximal tibiae of
immuno-deﬁcient SCID mice, either by direct injection through the cortical bone or surgical exposing and drilling on the tibial
metaphysis to seed tumor cells. Bone tumors were obvious on microCT within 4 weeks following osteosarcoma cell inoculation
through surgical delivery. In contrast, direct injection without drilling often resulted in periosteal tumors. Although neoplasms
were developed regardless of VEGF levels, orthotopic tumors derived from high VEGF-expressing cells were detected 2 weeks ear-
lier on CT images than the ones from VEGF negative cells. At sacriﬁce, high VEGF tumors were distinctively larger in size and
more frequently invaded the adjacent bone tissue. Multiple metastatic lesions were found in all the lung tissues at 8 weeks from
high VEGF group, whereas only 1 of 7 VEGF negative tumors exhibited pulmonary metastasis. Overall, this model developed
with the surgical tumor cell delivery results in histological and radiographic features more consistent with primary osteosarcoma.
Interestingly, VEGF expression correlates with the early establishment, rapid tumor growth, and the development of pulmonary
metastasis.
Copyright © 2007 Shang-You Yang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Osteosarcoma is a highly malignantbone tumor that usually
aﬀects adolescents and young adults. Multimodality treat-
ment consisting of aggressive adjuvant chemotherapy and
wide surgical resection has markedlyimproved prognosis in
osteosarcoma. However, nearly a half of the patients still
experience therapeutic failures [1]. Treatment of patients
with osteosarcoma, especially those nonresponsive to cur-
rent chemotherapy protocols, remains a major challenge.
Although the exact mechanisms of invasion into adjacent
tissues, the microcirculatory system, and lymphogenic or
hematogenic dissemination with subsequent extravasation
and formation of secondary tumor foci remain unclear, it
appears that high metastatic potential and recurrence rate
areassociatedwithpromotedneovascularization[2].Indeed,
growth, invasion, and metastasis of solid tumors are depen-
dent on neovascularization, which is regulated through an-
giogenesis [3]. The development of tumor angiogenesis is
believed to be dependent on the net balance between the
actions of angiogenesis promoters and inhibitors. Proangio-
genic factors are upregulated in malignancy, and have been
linked to poor prognosis with disease progression [4]. It
appears that the proangiogenic factors within solid tumors
stimulate host vascular endothelial cell mitogenesis and pos-
sibly chemotaxis. A large number of proangiogenic factors
have been identiﬁed, including basic ﬁbroblast growth fac-
tor (bFGF), platelet-derived growth factor (PDGF), trans-
forminggrowthfactorbeta-1(TGFβ1),transforminggrowth
factor alpha (TGFα), and epidermal growth factor (EGF)
[5]. Perhaps the best characterized one is vascularendothe-
lial growth factor (VEGF), which is relatively unique among
growth factors in terms of its speciﬁcity for the vascular en-
dothelium [6]. Enhanced VEGF gene expression has been
identiﬁed in a number of malignant tumors from breast,
lung, ovarian, liver, and colon in comparison with normal
tissue[7].However,therearefewstudiesaimedatelucidating
the correlation of VEGF expression and progression of os-
teosarcoma.Theobjectivesofthecurrentstudyaretocharac-
terize a murine model of human osteosarcoma with distinct2 Sarcoma
VEGF expressions to monitor VEGF expression in the de-
velopment and progression of this most common malignant
bone tumor.
2. MATERIALS AND METHODS
2.1. Animals
Severe combined immunodeﬁcient (SCID) mice at four
weeksofagewereobtainedfromtheJacksonLaboratory(Bar
Harbor,Me,USA)andusedashostsfortheexperimentalsar-
coma. The animals were housed in a pathogen-free environ-
ment and given free access to autoclaved chow and water. All




(CRL-1543) cells were obtained from American Type Cul-
ture Collection (Manassas, Va, USA) and processed accord-
ing to the vendor’s instruction. G-292 Cells were cultured in
McCoy’s 5a medium with 1.5mM L-glutamine and 2.2g/L
sodium bicarbonate, while HOS cells were maintained in
MEM (Eagle) medium with 2mM L-glutamine and 1.5g/L
sodium bicarbonate, 0.1mM nonessential amino acids, and
1.0mM sodium pyruvate. Both cell cultures also contained
10% fetal bovine serum (FBS), 100U/mL penicillin, and
100μg/mL streptomycin. Cells were incubatedat 37◦Ci na
5% CO2 incubator. Media were changed every 3days. When
90% conﬂuence was reached, culture medium was removed,
the cell layer rinsed thoroughly with phosphate buﬀered
saline (PBS), and enzymatically dissociated by adding 0.25%
(w/v) trypsin-0.03% (w/v) EDTA. Cells were maintained by
subculture at a ratio of 1 : 8. Prior to implantation, the cell
suspensionsweredilutedwith0.5%(w/v)trypanbluein0.16
mol/L ammonium chloride to assess cell viability and num-
ber.
2.3. Enzymelinkedimmunosorbentassay(ELISA)
Human VEGF levels in the culture medium collected from
G-292 (CRL-1423) and HOS (CRL-1543) cell cultures were
assessed using Quantikine ELISA kits (R&D Systems) with a
pair of rabbit anti-human VEGF antibodies (R&D Systems)
according to manufacture’s instruction and the standardized
protocol previously described [8].
2.4. Establishmentoftheorthotopicosteosarcoma
The Institutional Animal Investigation Committee approved
all animal procedures. SCID Mice were anesthetized by IP
injection of a mixture of Xylazine (8mg/kg) and Ketamine
(100mg/kg). Two diﬀerent approaches were utilized to de-
liver the osteosarcoma cells to the right tibiae of the mice.
In the surgical exposure group, under strict sterile condi-
tions,a0.5cmincisionalongthelateralcollateralligamentof
the knee was made to expose the proximal of tibia. A 0.8mm
dental drill was used to drill a small hole across the metaph-
ysis. The wound was rinsed with PBS containing Penicillin
G (500unit/mL) and Streptomycin (500μg/mL) before clos-
ing the skin cut by simple interrupted sutures. 100μLo fc u l -
ture medium containing 106 osteosarcoma cells (G-292 or
HOS) was injected into the hole immediately after surgery.
The other limb received a sham operation without injection
of tumor cells.
To compare with the surgical groups, mice were given a
direct injection of 106 G-292 or HOS cells through the cor-
tical bones into the proximal tibial metaphysis using a 23G
needle, without the surgical procedures described above. All
animals were monitored throughout the study with daily vi-
sual inspection for general health and tumor development.
A caliper was used to measure the leg dimensions to as-
sess growth of the tumor. Animals were sacriﬁced at 6 and
8 weeks after tumor cells inoculation by CO2 asphyxiation.
Legscontainingorthotopictumors,liver,andlungswerehar-
vested for histological and molecular evaluations.
2.5. MicroCTevaluation
An eXplore Locus MicroCT system (GE Medical Systems,
London, ON, Canada) was used to monitor the tumor
growth, characters of bone lesions, and lung metastasis.
Mice were scanned immediately following tumor cell im-
plantations, and every 2 weeks thereafter. All mice were fully
anesthetized (10mg/kg of Xylazine and 120mg/kg of Ke-
tamine) and restrained during each CT scanning. Scan pa-
rameters were set at 45μm isotropic voxel size, 400 projec-
tions, 400milliseconds exposure time, 80KW voltages, and
450μAc u r r e n t .
2.6. Histologyprocessandimmunohistological
(IHC)examination
Proximal tibiae bearing osteosarcoma tissue and receiving
sham operation were collected along with the lungs and liver
at sacriﬁce. Tissues were ﬁxed in buﬀered formalin, decalci-
ﬁedinEDTA(bonetissue),andembeddedinparaﬃnatc on-
sistent orientation. The bone tumors in tibia were cut longi-
tudinally and other tissues were cut in multiple layers. All tis-
sues were stained with hematoxylin and eosin, and examined
under a Zeiss light microscope. Digital photomicrographs
were captured and analyzed using Image-Pro Plus analysis
software (Media Cybernetics, Silver Spring, Md, USA). Tu-
mor length and width were measured, and metastatic lesions
were evaluated.
IHC was performed on primary orthotopic tumor sec-
tions to detect the expression levels of VEGF, Flt-1 (physio-
logical receptor of VEGF), and CD31, according to the in-
structions of the vender and the protocol published previ-
ously [9]. Brieﬂy, paraﬃns e c t i o n sw e r ed e p a r a ﬃnized in xy-
lene and rehydrated in graded alcohols and water. 0.3% Hy-
drogen Peroxide was applied to diminish endogenous per-
oxidase followed by microwave incubation to enhance the
antigen. After blocking with 1.5% normal goat serum for
1hour, the sections were incubated overnight with the pri-
mary antibodies (2μg/mL, BD, Pharmingen) in a moistur-
ized chamber at 4◦C. Biotin-conjugated secondary antibody
and Avidin-biotin enzyme reagents were sequentially appliedShang-You Yang et al. 3
for 30 minutes between extensive washes. The color was de-
veloped by adding 3.3
 -diaminobezidine tetrahydrochloride
(DAB). In negative control sections, an irrelevant antiserum
was applied at the same concentration as the primary anti-
body. Digital images were captured and analyzed using the
Image-Pro software package. The level of positive staining
and localization was evaluated in six diﬀerent ﬁelds and ex-
pressed as pixel density.
2.7. RNAextractionandreal-timequantitative
PCRforgeneexpression
Primary osteosarcoma tissues including the adjacent bone
were snapped-frozen in liquid nitrogen at the time of
sacriﬁce. The tumor tissues were ground into power while
deep-frozen and a portion of the tumor-bone powder
homogenized in 0.5mL of Trizol solution (Gibco BRL) using
a glass Grinder Pestle. Total RNA extraction was performed
using a commercial kit (Tel-Test Inc., Friendswood, Tex,
USA) in accordance with the manufacturer instructions. The
precipitated RNA was then treated with DNase and passed
through a spin column (Rneasy mini kit, Qiagen) for further
puriﬁcation. Reverse transcription and real-time PCR for
the expression of VEGF, c-myc,a n dc-fos was performed as
described previously [10] .B r i e ﬂ y ,c D N Aw a sr e v e r s et r a n -
scribed from 0.5μgo ft o t a lR N Ai n4 0μL reaction mixture
containing 1 × PCR buﬀer, 500μM each of deoxynucleotide
triphosphates (dNTP), 0.5U/μL of RNase inhibitor, 2.5μM
random hexamers, 5.5mM MgCl2, and 1.25 U/μLo fr e v e r s e
transcriptase (Perkin Elmer, Conn, USA); and incubated
in a DNA Thermal Cycler (Perkin Elmer, Mass, USA)
at 25◦C for 10minutes, 48◦Cf o r5 m i n u t e sf o l l o w e db y
95◦C for 5minutes. For real-time PCR steps, sense and
antisense primer pairs were picked in “Primer3” software
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgi)
and listed as follows: VEGF 5 -AAGGAGGAGGGCAGAA-
TCAT-3  and 5 -ATCTGCATGGTGATGTTGGA-3 ; c-myc
5 -GGTGGAAAACCAGGTAAGCA-3  and 5 -CCTTCT-
CCTCTGCCATCTTG-3 ; c-fos 5 -AAGGAGAATCCGA-
AGGGAAA-3  and 5 -AGGGCCCTTATGCTCAATCT-3 .
To standardize target gene level with respect to variabil-
ity in RNA and cDNA quality, house keep gene 18S was
coampliﬁed as an internal control. Reaction mixtures of
25μL containing 12.5μLo f2× SYBR Green PCR Master
Mix (5mM MgCl2, 200μM dATP, dCTP, dGTP, 400μM
dUTP, 1.25U AmpliTaq Gold DNA polymerase, 0.5U
AmpErase uracil N-glycosylase), 0.5μLe a c ho f0 . 4μMt a r g e t
primers and 2μL of cDNA. The PCR reactions were set in
MicroAmp optical 96-well reaction plates with MicroAmp
optical caps and ampliﬁed in the ABI Prism 7700 Sequence
Detector (PE-Applied Biosystems, Foster City, Calif, USA)
for 40 cycles (95◦C for 15seconds, 60◦Cf o r1m i n u t e ) .T h e
ﬂuorescent signals were recorded dynamically. The values
of threshold cycle (Ct) at which a statistically signiﬁcant
increase in reporter-dye signals (ΔRn) is ﬁrst detected
were imported into Microsoft Excel program and used
to calculate the relative quantiﬁcation of the target gene
expression. With the Ct value of 18S the samples as an
internal control and mean Ct value of target gene expres-
sion from the bone tissue of the sham operations as the
calibrator samples (named 0% expression change), the
comparative gene expressions of the experimental tumor
groups over the sham controls were calculated accord-
ing to the formula given in the manufacturer’s manual
[11].
2.8. Statisticalanalyses
A total of 40 mice were used for this study with 2 premature
deaths (anesthetics overdose, eliminated from the study).
Statistical analysis between diﬀerent VEGF expressing tumor
groups was performed by Student t-test, or the ANOVA test;
with the Schafer formula for post hoc multiple comparisons,
using the SPSS software package (SPSS. Chicago, Ill, USA).
A P value of less than .05 was considered as signiﬁcant dif-




ELISA was performed to determine VEGF expression levels
in medium after 72hours of cell culture. There were only
trace levels of VEGF expressed in the culture media collected
from the dishes of the HOS (CRL-1543) cells. However, the
VEGF level in media of G-292 (CRL-1423) cells was over 27
times higherthan the level detected in media of HOS cells
during the same culture period of time.
3.2. Primaryorthotopicosteosarcomagrowth
Regardless of the VEGF expression, osteosarcoma cells from
both lines induced orthotopic tumors in the upper tibia re-
gion of the SCID mice. Daily measurement of the legs for




sues. On the other hand, the diﬀerent methods of tumor cell
inoculation resulted in varying growth patterns of the ortho-
topic tumors. Surgical exposure and drilling of the tibia pro-
moted cell anchoring and resulted in intramedullary lesions
(Figures 1(a) and 1(b)). Any surrounding soft tissue bulging
was not obvious until 6 weeks after cell transplantation. Tu-
mors established using direct injection of osteosarcoma cells
resulted in primary tumors anchored to adjacent periostea





G292 cells (high VEGF expression) developed detectable
bone tumors at 2 weeks after tumor cell inoculation, whereas
the HOS cells-(low VEGF expression) derived tumors be-
came detectable in microCT images at either 4 weeks or 64 Sarcoma
(a) (b) (c) (d)
Figure 1: Two methods to establish the orthotopic tumors: panel (a) shows surgical exposure of the proximal tibia plus drilling a hole
through cortical bone to accommodate osteosarcoma cells (25× magniﬁcation); panel (b) shows a high magniﬁcation (200×) of orthotopic
bone tumor with the surgical method. Panels (c) and (d) example the tumor by direct injection of tumor cells to proximal tibia, mostly out
growth surrounding the bone (25 × and 200 ×).
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 2: MicroCT images of the orthotopic osteosarcoma model. Panels (a) and (e) shows 7 days after G292 tumor cells inoculation; (b)
and (f) show 2 weeks; Panels (c) and (g) show 4 weeks; and panels (d) and (h) show 8 weeks after the tumor cells transfer. Lower panels show
the 3D isosurfaces of the tibia harboring tumors.
weeks after inoculation (P<. 05). Periodical microCT scans
dynamically monitored the development and growth of the
primary tumor and proved a useful assessment technique in
this study. Figure 2 reveals an example of the progression of
the experimental osteosarcoma (G292 cells).
Histology evaluation using a computerized image anal-
ysis system showed that the average sizes (observed areas
on sections) of the primary tumors derived from G292 cells
were 3.97 ± 0.84 × 2.95 ± 0.24mm (length × width), sig-
niﬁcantly larger than HOS experimental orthotopic tumors
(1.85 × 1.34)mm at 8 weeks, the termination point of the
experiment (P<. 05). In addition, immunohistochemi-
cal staining revealed strong positive CD31 (Figure 3(a))a n d
VEGF(Figure 3(c))stainingonG292cell-derivedorthotopic
tumor sections, in comparison with the tumors from HOS
cells (Figures 3(b) and 3(d)).
3.4. Molecularassessment
RNA samples isolated fromthe orthotopic tumors were ex-
amined for the gene expression of VEGF, Flt-1, and both
oncogenes c-fosandc-myc.Relativegeneexpressions overthe
sham controls were calculated. Signiﬁcant higher VEGF ex-
pression wascompanionedwithelevated c-myc expressionin
G292-derived primary tumors (Figure 4).
3.5. Remotetumormetastasis
Lungs and liver were collected and pathologically exam-
ined for tumor metastasis. No emerging metastatic lesions
were identiﬁed in liver tissues. However, all of the G292-
experimental osteosarcoma mice sacriﬁced at 8 weeks and
80% of the mice at 6 weeks developed extensive lungShang-You Yang et al. 5
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(c) (d)
Figure 3: Immunohistochemical staining of the orthotopic osteosarcoma models. Micrographs (a) and (c) were tumors derived from high
VEGFG-292cells;while(b)and(d)weresamplesfromHOScelltransplantation.(a)and(b)werestainedwithantihumanVEGFantibodies;
and (c) and (d) were against antihuman CD31.
































































Figure 4: Comparative gene expression quantiﬁcation using sham
operated bone tissue as controls. Data expressed as the relative ex-
pressions over those from sham bone tissu(∗P<. 05).
metastasis lesions (Figure 5). In comparison, only 1 out of
7 HOS-tumor mice developed a similar pulmonary change
within the same time.
4. DISCUSSION
The current study establishes a mouse model of osteosar-
coma by introducing human osteosarcoma cells to the com-
mon disease site-proximal tibia-in immune deﬁciency mice.
Using two clonally unrelated human osteosarcoma cell lines,
wetrytocomparesthecorrelationbetweenVEGFexpression
andthedevelopmentandprogressionofosteosarcomainthis
murine model. Osteosarcoma is an extremely aggressive ma-
lignant tumor of the skeleton characterized by fast growth
and early hematogenic metastasis. It is postulated that the
growth, invasion, and metastatic potential of many solid tu-
mors are dependent on angiogenesis mediated via the potent
proangiogenic factor VEGF. Clinical studies have shown that
the density of intratumoral microvessels correlates well with
the grade of invasiveness, the frequency of metastasis, and
clinical prognosis in many types of cancers [12, 13]. Malig-
nancies have an absolute requirement for a persistent sup-
ply of new blood vessels to nourish their growth and to fa-
cilitate metastasis. The angiogenic cascade leading to tumor
vascularization can be divided into two general phases, the
prevascular phase and the vascular phase [5, 14]. Once tu-
mor cells transform into angiogenic phenotype, these ma-
lignant cells in avascular tumors become capable of induc-
ing neovascularization, which permits a rapid rate of tu-
mor growth and increases metastatic potential. The devel-
opment of tumor angiogenesis is believed to be dependent
on the elevated expression and presence of active proangio-
genic factors within the solid tumors that stimulate host vas-
cular endothelial cell mitogenesis and possibly chemotaxis
[4].VEGF(themostpotentdirect-actingproangiogenicpro-
tein known) is a diﬀusible endothelial cell-speciﬁc mitogen
and an angiogenic factor that also increases vascular perme-
ability. It stimulates and maintains neovascularization in a
variety of tumor types [6]. In situ hybridization assays have
shown a marked upregulation of VEGF mRNA in many hu-
man tumors [15], and VEGF mRNA has been found to be
much more abundant in cancer cells than in endothelium,
suggesting that the cancer cells themselves generate VEGF to
induce angiogenesis through a paracrine loop. However, lit-
tle is known about the role of angiogenesis and proangio-
genic factors, such as VEGF, in the development and biologic6 Sarcoma
(a) (b) (c)
Figure 5: Pulmonary metastasis of the experimental osteosarcoma established by G292 cells. Lung sections stained with H & E. Panel (a) is
a micrograph at 25 × magniﬁcation, (b) shows the metastatic lesion at 200 ×, while panel (c) at 400 × magniﬁcation.
activity of malignant bone tumors [16] though several clini-
cal studies have found that many osteosarcoma patients with
pulmonary metastasis had primary tumors with high levels
of VEGF expression [17]. In this study, we utilized estab-
lishedosteosarcomacelllineswithdistinctVEGFexpressions
to generate an experimental orthotopic osteosarcoma mouse
model. The data clearly show that the orthotopic tumors de-
rived from high VEGF expressing osteosarcoma cells (G292)
grew more rapidly and were more likely to metastasize to the
lung by 6–8 weeks. In contrary, the experimental orthotopic
tumors derived from low VEGF expressing cells were less in-
clined toward early pulmonary metastasis. The data provides
a VEGF targeting osteosarcoma model to all further studies
tounderstandtheroleofVEGFinthepathogenesis,progress,
and prognosis of the tumor.
With the recent expansion of molecular biology tech-
niques, genetic alterations, associated the development and
metastases of malignant tumors, have been observed. Cellu-
lar oncogenes have been found to be activated by DNA re-
arrangements (proviral insertions, chromosome transloca-
tions, and DNA ampliﬁcations). These alterations may re-
sultinanincreasedorderegulatedgeneexpression.Although
numerous oncogenes and tumor suppressor genes have been
identiﬁed in osteogenic sarcomas, c-myc and c-fos seem to
be expressed with a relatively high incidence [18–22]. C-myc
protooncogene on chromosome 8 encodes transcription fac-
tor, which involves in the regulation of cell growth, DNA
replication, and transcriptional regulation of speciﬁc target
genes [23]. C-fos protooncogene, the cellular homologue of
v-fos, is involved in osteoblast and chondrocytes diﬀerentia-
tion [21]. Studies have indicated that c-myc and c-fos were
found overexpressed in the relapse osteosarcoma and the
metastasis cases [19]. In this G292 experimental osteosar-
comamodel,theseoncogenes,especiallyc-myc,mark edlye x-
pressed in the tumor tissues supplementing with the high
VEGF expression.
To our knowledge, there are only a few reports con-
cerning experimental murine models of osteosarcoma [24,
25]. Luu et al. recently reported an orthotopic osteosar-
coma model by injecting three related human osteosarcoma
lines (TE85, MNNG/HOS, and 143B) to proximal tibia of
athymic nude mice [25]. Coincidentally, the authors used
the N-methyl-N
 -nitro-N-nitrosoguanidine (MNNG) trans-
formed HOS osteosarcoma cells in their model and found
that the cells resulted in tumorigenesis in primary injection
site, but signiﬁcant less pulmonary metastasis compared to
the other cell line (143B). Since MNNG is known to create
DNA strand breakage, it is postulated that the mutagen may
cause the genetic alteration and be responsible for the phe-
notypic diﬀerence in tumor growth and metastatic potential
[25]. We utilized the original HOS cells in our model, and
predictable primary tumors were established in upper tibiae
of SCID mice. However, the pulmonary metastasis was not
evident, in agreement with Luu’s ﬁndings [25]. One of the
major characteristics of HOS cells is their low expression of
VEGF, that is, experimental evaluations have been perform-
ing to test the hypothesis that the slower neo-angiogenesis in
primary tumors due to lack of VEGF contributes to the de-
layed remote metastasis of osteosarcoma.
Kaya et al. [17] examined 27 human cases of primary os-
teosarcomas and evaluated the correlation between the ex-
pression of VEGF and presence of microvessels, the clinical-
pathological variables, and the survival of patients. Their in-
vestigation suggested that patients with VEGF-positive os-
teosarcoma developed a signiﬁcantly higher lung metastasis
rate and therefore a reduced chance of survival. It appears
that antiangiogenic therapy, especially the blockade of VEGF
eﬀects may be a novel and potentially promising strategy
for this common form of malignant tumor in orthopaedic
surgery. The VEGF-associated osteosarcoma mouse model
we are reporting here may provide a platform to screen po-
tential interventions, including antiangiogenic gene therapy,
for osteosarcoma.
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